Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KALA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALAKALA BIO$8.32+3.1%$5.90$2.92▼$11.20$58.41M-1.81183,835 shs134,983 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALAKALA BIO0.00%+12.74%+44.95%+128.57%+36.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKALAKALA BIO4.0038 of 5 stars3.52.00.04.42.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALAKALA BIO 3.00Buy$13.0056.25% UpsideCurrent Analyst Ratings BreakdownLatest KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/2/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.005/23/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.00(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALAKALA BIO$3.89M15.01N/AN/A$2.02 per share4.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALAKALA BIO-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%N/ALatest KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025KALAKALA BIO-$1.82-$1.71+$0.11-$1.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKALAKALA BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALAKALA BIO3.192.102.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALAKALA BIO24.61%Insider OwnershipCompanyInsider OwnershipKALAKALA BIO8.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKALAKALA BIO307.02 million6.44 millionNot OptionableKALA HeadlinesRecent News About These CompaniesHC Wainwright Has Positive Estimate for KALA BIO Q3 EarningsAugust 17 at 9:26 AM | marketbeat.comEquities Analysts Offer Predictions for KALA BIO Q3 EarningsAugust 16 at 2:56 AM | americanbankingnews.comWall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to TradeAugust 13, 2025 | zacks.comKALA BIO (NASDAQ:KALA) Downgraded to Sell Rating by Wall Street ZenAugust 12, 2025 | americanbankingnews.comKALA BIO, Inc.: KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 8, 2025 | finanznachrichten.deKala Bio (KALA) Q2 Loss Widens 15%August 8, 2025 | aol.comAKALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 8, 2025 | globenewswire.comKALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 6, 2025 | globenewswire.comKALA BIO (KALA) to Release Earnings on TuesdayJuly 30, 2025 | marketbeat.comKALA BIO (NASDAQ:KALA) Upgraded by Wall Street Zen to Hold RatingJuly 28, 2025 | marketbeat.comAnalyst Coverage Sparks Interest in These 4 Stocks Amid VolatilityJuly 25, 2025 | zacks.comKALA Bio completes enrollment of CHASE clinical trialJuly 12, 2025 | ophthalmologytimes.comOKALA BIO Announces Completion of Enrollment in CHASE Clinical Trial ...July 11, 2025 | morningstar.comMKALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial ... - NasdaqJuly 11, 2025 | nasdaq.comKALA BIO Inc. (KALA) Stock Price Today - WSJ - The Wall Street JournalJuly 10, 2025 | wsj.comKALA BIO, Inc.: KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)July 9, 2025 | finanznachrichten.deKala Pharmaceuticals Completes Enrollment for Phase 2b TrialJuly 9, 2025 | tipranks.comKALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)July 9, 2025 | globenewswire.comKala Bio Inc Valuation - MorningstarJuly 8, 2025 | morningstar.comMKALA BIO, Inc. (KALA) - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comKALA BIO, Inc. (NASDAQ:KALA) CFO Sells $14,560.31 in StockJune 27, 2025 | insidertrades.comMedia Sentiment Over TimeKALA Company DescriptionsKALA BIO NASDAQ:KALA$8.32 +0.25 (+3.10%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$8.15 -0.17 (-1.98%) As of 08/15/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access